Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity48–53”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Self-citationActivation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.
Cartwright, C. A., Meisler, A. I., & Eckhart, W. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.2.558 · Cited by 277
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251
Self-citationPreclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
Kopetz, S., Lesslie, D. P., Dallas, N. A., Park, S. I., Johnson, M., Parikh, N. U., Kim, M. P., Abbruzzese, J. L., Ellis, L. M., Chandra, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2246 · Cited by 160
Self-citationCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
Research works printed but not linked: 25
- Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA: Cancer J Clin 64(2):104–17
- Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE et al (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85(4):786–95 · DOI · Paper page
- Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13):5090–101
- Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–72 · DOI · Paper page
- Penuel E, Martin GS (1999) Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol Biol Cell 10(6):1693–703 · DOI
- Xie G, Peng Z, Raufman JP (2012) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006–15 · DOI · Paper page
- Chen J, Elfiky A, Han M, Chen C, Saif MW (2014) The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 13(1):5–13 · DOI
- Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS et al (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110–20 · DOI · Paper page
- Hennequin L, Allen J, Costello GF et al (2005) The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res 46:A2537
- Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI et al (2010) Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res : Off J Am Assoc Cancer Res 16(19):4876–83 · DOI · Paper page
- Gangadhar TC, Clark JI, Karrison T, Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investig New Drugs 31(3):769–73 · DOI · Paper page
- Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investig New Drugs 30(3):1158–63 · DOI
- Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–53
- Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20(3):179–84 · DOI · Paper page
- Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306–11 · DOI · Paper page
- Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD et al (2014) A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85(2):245–50 · DOI
- Messersmith WA NS, Arcaroli J et al. (2010) A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic paancreatic cancer. Journal of Clinical Oncology. Suppl: abstr e14515 · DOI
- Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L et al (2014) A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer 15(1):52–7 · DOI
- Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E et al (2012) A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investig New Drugs 30(2):779–86 · DOI
- McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M et al (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 25(10):1988–95 · DOI
- Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res : Off J Am Assoc Cancer Res 14(13):4284–91 · DOI · Paper page
- Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD et al (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273(2):1052–7 · DOI · Paper page
- Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C et al (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investig New Drugs 32(2):330–9 · DOI
- Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 23(3):610–7 · DOI
- Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T et al (2014) Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 19(4):348–9 · DOI
Cited by
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer
Cekaite, L., Eide, P. W., Lind, G. E., Skotheim, R. I., & Lothe, R. A. (2016) · Oncotarget · doi:10.18632/oncotarget.6390 · Cited by 84
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
Dual Drug Repurposing: The Example of Saracatinib
Ramos, R., & Vale, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084565 · Cited by 24
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Reddy, S. M., Kopetz, S., Morris, J., Parikh, N., Qiao, W., Overman, M. J., Fogelman, D., Shureiqi, I., Jacobs, C., Malik, Z., Jimenez, C. A., Wolff, R. A., Abbruzzese, J. L., Gallick, G., & Eng, C.
- Venue
- Investigational New Drugs
- Published
- 2015-06-12
- Volume
- 33
- Issue
- 4
- Pages
- 977-984
- ISSN
- 0167-6997
- 1573-0646
- Cited by
- 45
- References
- 14
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. https://app.cochat.ai/papers/10.1007/s10637-015-0257-z
- The paper
- Reddy, S. M., Kopetz, S., Morris, J., Parikh, N., Qiao, W., Overman, M. J., Fogelman, D., Shureiqi, I., Jacobs, C., Malik, Z., Jimenez, C. A., Wolff, R. A., Abbruzzese, J. L., Gallick, G., & Eng, C. (2015). Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-015-0257-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.